Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Pharma industry loses on Medicare price ...

Federal judges in Texas and Connecticut on Thursday ruled against arguments challenging the constitutionality of the Medicare ...

Drug companies have formed a new group to present lawmakers with research on what the industry sees as the negative impacts ...

Pharmaceutical companies were dealt back-to-back blows over the last 24 hours in their fight against the Biden-era Medicare ...

An appeals panel found that a pharmaceutical company's participation in Medicare's drug price negotiation program is ...

Three federal courts reject legal challenges to Medicare drug price negotiation Judges side with government in cases filed by ...

Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic ...

The drug price negotiation program has withstood another procedural effort in striking down one of the Inflation Reduction Act’s most significant provisions. | A federal court of appeals judge upheld ...

The drug industry’s top lobbying group is appealing its latest loss in its challenge to Medicare’s Drug Price Negotiation Program to the Fifth Circuit, returning the case to an appeals court that has ...

Boehringer Ingelheim Pharmaceuticals Inc. failed to prove to an appeals court that a Biden-era drug pricing program aimed at ...

The One Big Beautiful Bill Act ("OBBB") expands exemptions for orphan drugs from mandatory Medicare price negotiations and modifies their eligibility timeline.